Evidence map›Paper›PMID 35792280›Full record

ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2022

Evidence of co-infections during Delta and Omicron SARS-CoV-2 variants co-circulation through prospective screening and sequencing.

Patricia Combes, Maxime Bisseux, Antonin Bal, Pierre Marin, Justine Latour, Christine Archimbaud, Amélie Brebion, Hélène Chabrolles, Christel Regagnon, Jérémy Lafolie and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 3 countries.

Patricia CombesCHU Clermont-Ferrand, pôle BMAP, F-63003 Clermont-Ferrand, France.
Maxime BisseuxCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.
Antonin BalGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.
Pierre MarinCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France.
Justine LatourCHU de Toulouse, Virology Laboratory, F-31300 Toulouse, France.
Christine ArchimbaudCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.
Amélie BrebionCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France.
Hélène ChabrollesCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.
Christel RegagnonCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France.
Jérémy LafolieCH Vichy, Laboratory Department, F-03000 Vichy, France.
Gregory DestrasGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.
Bruno SimonGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.
Jacques IzopetCHU de Toulouse, Virology Laboratory, F-31300 Toulouse, France; INFINITY, INSERM UMR291-CNRS UMR5051-Toulouse University, F-31300 Toulouse, France; Université Toulouse III Paul Sabatier, F-31300 Toulouse, France.
Laurence JossetGenEPII Sequencing Platform, Institut des Agents Infectieux, Hospices Civils de Lyon, F-69004 Lyon, France; CIRI, Centre International de Recherche en Infectiologie, Team VirPath, Univ Lyon, Inserm U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007 Lyon, France.
Cécile HenquellCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France.
Audrey MirandCHU Clermont-Ferrand, 3IHP, Virology Laboratory, National Reference Centre for Enteroviruses and parechoviruses-associated laboratory, F-63003 Clermont-Ferrand, France; Université Clermont Auvergne, CNRS 6023-LMGE, EPIE, F-63001 Clermont-Ferrand, France. Electronic address: amirand@chu-clermontferrand.fr.
Université Clermont Auvergne · FRCentre Hospitalier Universitaire de Toulouse · FRHôpital de la Croix-Rousse · FRInstitut Européen De La Qualité Totale · FRInstitut Mérieux (France) · FRInstitut Toulousain des Maladies Infectieuses et InflammatoiresInteraction Hôtes Agents Pathogènes · FRTerra · NLUniversité Claude Bernard Lyon 1 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo describe Delta/Omicron SARS-CoV-2 variants co-infection detection and confirmation during the fifth wave of COVID-19 pandemics in France in 7 immunocompetent and epidemiologically unrelated patients.

methodsSince December 2021, the surveillance of Delta/Omicron SARS-CoV-2 variants of concern (VOC) circulation was performed through prospective screening of positive-samples using single nucleotide polymorphism (SNP) PCR assays targeting SARS-CoV-2 S-gene mutations K417N (Omicron specific) and L452R (Delta specific). Samples showing unexpected mutational profiles were further submitted to whole genome sequencing (WGS) using three different primer sets.

resultsBetween weeks 49-2021 and 02-2022, SARS-CoV-2 genome was detected in 3831 respiratory samples, of which 3237 (84.5%) were screened for VOC specific SNPs. Unexpected mutation profiles suggesting a dual Delta/Omicron population were observed in 7 nasopharyngeal samples (0.2%). These co-infections were confirmed by WGS. For 2 patients, the sequence analyses of longitudinal samples collected 7 to 11 days apart showed that Delta or Omicron can outcompete the other variant during dual infection. Additionally, for one of these samples, a recombination event between Delta and Omicron was detected.

conclusionsThis work demonstrates that SARS-CoV-2 Delta/Omicron co-infections are not rare in high virus co-circulation periods. Moreover, co-infections can further lead to genetic recombination which may generate new chimeric variants with unpredictable epidemic or pathogenic properties that could represent a serious health threat.

Indexed as

CoinfectionCOVID-19HumansProspective StudiesSARS-CoV-2Sequence AnalysisDelta and Omicron VOCRecombinationSARS-CoV-2 co-infectionSingle nucleotide polymorphism screeningWhole genome sequencing

Identifiers

PMID35792280
PMCPMC9250411
OpenAlexW4283786239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.